Eli Lil­ly, Boehringer In­gel­heim get ap­proval to ex­pand Jar­diance, Syn­jardy la­bels to kids with type 2 di­a­betes

Eli Lil­ly and Boehringer In­gel­heim won FDA ap­proval to ex­pand em­pagliflozin’s la­bel to in­clude ado­les­cents with type 2 di­a­betes.

The SGLT2 in­hibitor, bet­ter known as Jar­diance, was first ap­proved to im­prove glycemic con­trol in adults with type 2 di­a­betes in 2014. On Tues­day, the drug un­der the brand name Jar­diance re­ceived an ex­pand­ed la­bel to low­er blood sug­ar in 10- to 17-year-old pa­tients with type 2 di­a­betes in con­junc­tion with di­et and ex­er­cise. It’s al­so now ap­proved in com­bi­na­tion with met­formin, the on­ly oth­er oral ther­a­py avail­able for chil­dren with type 2 di­a­betes, for the 10 to 17 age group, for which it will be mar­ket­ed as Syn­jardy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER